论文部分内容阅读
目的探讨吉西他滨(Gem)联合卡铂治疗复发性上皮性卵巢癌的有效性和不良反应。方法采用随机对照研究的方法,将2008-08-2010-12间在川北医学院附属医院收治的48例复发性上皮性卵巢癌患者随机分为研究组(Gem联合卡铂)和对照组(紫杉醇联合卡铂),对其疗效及不良反应进行比较。结果对照组和研究组完全缓解率(CR)分别为12.5%和29.17%,总有效率分别为45.83%和79.17%,不良反应分别提高54.17%和25.00%。研究组CR和总有效率明显高于对照组(P<0.01),研究组治疗后不良反应明显低于对照组(P<0.01)。结论 Gem联合卡铂治疗复发性上皮性卵巢癌的临床疗效较好,不良反应较低。
Objective To investigate the efficacy and adverse reactions of gemcitabine (Gem) combined with carboplatin in the treatment of recurrent epithelial ovarian cancer. Methods Forty-eight patients with recurrent epithelial ovarian cancer who were treated in Affiliated Hospital of North Sichuan Medical College from 2008-08 to 2010-12 were randomly divided into study group (Gem combined with carboplatin) and control group (paclitaxel Combined carboplatin), its efficacy and adverse reactions were compared. Results The complete remission rate (CR) of the control group and the study group were 12.5% and 29.17% respectively. The total effective rates were 45.83% and 79.17% respectively. The adverse reactions were increased by 54.17% and 25.00% respectively. The CR and total effective rate of the study group was significantly higher than that of the control group (P <0.01). The adverse reaction rate of the study group was significantly lower than that of the control group (P <0.01). Conclusion Gem combined carboplatin in the treatment of recurrent epithelial ovarian cancer has good clinical efficacy and low adverse reactions.